To cite this article: Kim BJ, Day RW, Davis CH, Narula N, Kroll MH, Tzeng CWD, Aloia TA. Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective. J Thromb Haemost 2017; 15: 2158-64.
Summary. Background: The incidence of venous thromboembolism (VTE) after liver surgery remains high. Objective: To evaluate the safety and efficacy of extended pharmacologic thromboprophylaxis after liver surgery for the prevention of VTE. Patient/Methods: From August 2013 to April 2015, 124 patients who underwent liver resection for malignancy were placed on an extended pharmacologic thromboprophylaxis protocol. Intraoperative VTE prophylaxis included thromboembolic deterrent hoses and sequential compression devices. Once hemostasis had been ensured following hepatectomy, daily anticoagulant VTE prophylaxis was initiated for the duration of hospitalization. After hospital discharge, the large majority of patients (114, 91.9%) continued to receive anticoagulant thromboprophylaxis (enoxaparin) to complete a total course of 14 days after minor/minimally invasive hepatectomy or 28 days after major hepatectomy or a history of VTE. Results: The cohort included 39 (31.2%) major hepatectomies and 38 (31.5%) minor/minimally invasive approaches. The intraoperative, postoperative and overall transfusion rates were 5.6%, 8.1%, and 10.5%, respectively. Pharmacologic thromboprophylaxis was started on postoperative day (POD) 0 for 40 (32.3%) patients and on POD 1 for 84 (67.7%) patients. During 90 days of follow-up, no postoperative symptomatic deep vein thrombosis or pulmonary embolic events were diagnosed. Standard-protocol computed tomography scans of the chest, abdomen and pelvis that were obtained for 112 (90.3%) study patients showed no pulmonary emboli, or other thoracic, splanchnic or ileofemoral vein thromboses. Two (1.6%) patients had minor bleeding events that resolved after discontinuation of enoxaparin, requiring neither blood transfusion nor reoperation. The severe complication rate was 5.6%, with no 90-day mortalities. Conclusions: These preliminary data suggest that
Introduction
Despite an increasing magnitude and complexity of hepatectomy, the safety of modern-era liver surgery has seen a significant improvement [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . However, rates of postoperative venous thromboembolism (VTE) remain significant, at 1-5%, consistently double the rate associated with colorectal surgery. Data from the American College of Surgeons National Surgical Quality Improvement Project (ACS-NSQIP) database demonstrate a 2.9% rate of symptomatic postoperative VTE among 5706 liver resection patients [11] . Subsequent analysis of the ACS-NSQIP database revealed that one-third of symptomatic posthepatectomy VTEs were diagnosed after hospital discharge [12] . Despite the publication of guidelines [13] , a specific protocol that includes pharmacologic prophylaxis for VTE after hepatectomy has not been unanimously agreed upon, and the role for anticoagulation remains controversial.
Historically, liver surgeons have tended to avoid postoperative VTE chemoprophylaxis, owing to a perceived risk of perioperative bleeding [11] . The practice of complete avoidance or late initiation of thromboprophylaxis after a decline in the International Normalized Ratio (INR) was further supported by an erroneous misconception that postoperative liver insufficiency, which is particularly common following major and extended hepatectomies, leads to coagulopathy that protects against VTE. More recent data, however, have defined the concept of 'rebalanced coagulation' [14] , and suggest that patients are usually in a prothrombotic state after hepatectomy [15, 16] .
Following a Clinical Practice Guidelines Conference Series focused on venous thromboembolism prophylaxis in liver surgery at the Americas Hepato-Pancreato-Biliary Association Annual Meeting, it was recommended that 'postoperative anticoagulant thromboprophylaxis be routinely initiated immediately after hepatectomy in hemodynamically stable patients with no evidence for bleeding and should be continued at least until hospital discharge or return of full mobility' [13] .
Although postoperative VTE risk rises with the magnitude of hepatic resection and extends beyond hospital discharge, there are no published data on the use of extended pharmacologic thromboprophylaxis in liver surgery [12] . The purpose of this retrospective study was to assess the safety and efficacy of an extended thromboprophylaxis program following postoperative inpatient thromboprophylaxis in patients undergoimg oncologic liver surgery.
Methods

Data acquisition and patients
All patients who underwent hepatectomy (T.A.A.) from August 2013 to April 2016 and were treated with early postoperative and extended chemoprophylaxis were identified from a prospectively maintained liver resection database maintained in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center.
Preoperative , and/or catheter-associated thrombosis), number of intraoperative and postoperative transfusions, major and nonmajor bleeding events, platelet count nadir, peak PTT, peak PT, peak INR, renal insufficiency/renal failure, respiratory failure, liver failure, bile leak, return to operating room (ROR), cardiac arrest, stroke, coma, myocardial infarction, sepsis/septic shock, pneumonia, pleural effusion, surgical site infection, organ space infection, fascial dehiscence, urinary tract infection, length of stay, 30-day mortality, and 90-day mortality. Postoperative bile leak and liver failure were defined according to International Study Group of Liver Surgery standards [19, 20] . Major bleeding was defined as a fall in hemoglobin of 2 g dL À1 in 24 h, bleeding into a major organ, or any bleeding that required reintervention; all other bleeding was classified as non-major bleeding. All complications were collected and graded in real time by use of the Modified Accordion Grading system [21, 22] , and reviewed by two surgical staff members. Severe complications were defined as Accordion grade 3-5.
Follow-up and radiographic VTE assessment
After liver surgery, all patients were planned to be followed up for at least 5 years on a set schedule of imaging, laboratory investigations, tumor markers and physical examinations every 3-4 months for 2 years, then every 6 months for 2 years, and then annually. No patients in this study were lost to follow-up, and each patient was followed for at least 1 year. When patients had visits with local providers, clinical notes, laboratory results and imaging results were recovered for review. Within 3 months of surgery, 90.3% of patients underwent routine staging/surveillance imaging with standard contrastenhanced computed tomography (CT) of the chest, abdomen, and pelvis. Asymptomatic VTE was defined as any CT imaging finding of thrombosis of a catheter-associated vessel, pulmonary artery, or other thoracic, splanchnic or ileofemoral vein, including a specific diagnosis of DVT and/or PE.
Thromboprophylaxis protocol
The extended thromboprophylaxis protocol for liver resection was initiated in August 2013. Preoperative anticoagulation consisted of thromboembolic deterrent hoses and sequential compression devices, which were activated prior to anesthesia induction [23, 24] . The first dose of anticoagulant VTE prophylaxis was guided by standardized postoperative order sets, which initiated anticoagulant thromboprophylaxis when hemostasis was ensured, either in the post-anesthesia care unit or on the morning of postoperative day (POD) 1.
All patients in this study were started on subcutaneous unfractionated heparin (5000 mg every 8 h), converted to daily subcutaneous enoxaparin (40 mg) between POD 1 and POD 3, and continued on enoxaparin for the remainder of the hospitalization. Weight-based and renal dosing were utilized when appropriate. Although postoperatively monitored coagulation parameters were variably elevated in proportion with the magnitude of hepatectomy, no changes in thromboprophylaxis were made unless there was a clinical indication, such as bleeding. The extended prophylaxis protocol consisted of the following: after minimally invasive and/or minor hepatectomies, anticoagulant thromboprophylaxis was extended for 14 total days from the day of surgery, and after major hepatectomy, in those patients discharged with a drain or with a history of VTE, for a total of 28 days. A schematic diagram of the perioperative protocol is shown in Fig. 1 . All six patients receiving therapeutic-dose VTE prophylaxis to treat a recent preoperative VTE were restarted on their therapeutic-dose regimen at discharge.
Statistical analysis and Institutional Review Board approval
Continuous variables are reported as a median value and range/interquartile range (IQR) or a mean with a standard deviation. With 124 patients in this sample, the study is powered with a 74% to detect a statistically significant difference in postoperative VTE rates from 2.9% (national average) to 0% (current study) with an a error rate of 0.10. Statistical analyses were performed with SPSS STATISTICS 21 (IBM, Armonk, NY, USA). Analyses of these data were approved by our Institutional Review Board.
Results
One hundred and twenty-four patients were included in this study. ). Heparin-induced thrombocytopenia testing was performed in selected patients with significant platelet count changes, and never gave positive results in this cohort. The median length of stay was 5 days (IQR 3-6 days). The severe complication rate was 5.6%, with one patient requiring ROR for a non-hemorrhagic indication. There were no 90-day deaths.
During follow-up, which was complete in all patients, there were no symptomatic VTE (Poisson confidence interval: 0-3%) events in this series (Table 2) . One hundred and twelve (90.3%) patients underwent standard intravenous contrast CT scans of the chest, abdomen and pelvis within 90 days of the operation. None of these patients was diagnosed with VTE on the basis of these imaging studies, indicating that no patients developed a major 'rebound' thrombosis after withdrawal of extended low molecular weight heparin (LMWH). Six (4.8%) patients preoperatively presented on anticoagulant therapy for a previous VTE that was diagnosed > 90 days before surgery; in all cases, these patients were discharged on the extended prophylaxis regimen and transitioned back to a therapeutic-dose regiment between POD 14 and POD 28. None of these six patients had progression of previous thrombosis or a new VTE. Although one patient returned to the operating room, the indication was wound dehiscence, not hemorrhage. Two patients (1.6%) did have minor postoperative bleeding leading to discontinuation of pharmacologic thromboprophylaxis; in both cases, this resulted in bleeding cessation, and neither patient required transfusion or reintervention.
Discussion
Hepatobiliary surgery presents unique challenges, with a specific need to have effective hemostasis at the operation site while avoiding venous thrombosis at other sites. These challenges are compounded by concomitant physiologic alterations in prothrombotic and antithrombotic coagulation factors. Compelling data now indicate that the majority of these patients are prothrombotic following liver surgery, that the degree of VTE risk increases with the magnitude of resection, and that as many as one-third of events are diagnosed within 30 days of discharge [12] . Together, these findings suggest the need for meticulous operative techniques, the judicious use of mechanical and pharmacologic VTE prophylaxis, and fastidious postoperative management. The aims of this study were to determine the safety and efficacy of early initiation combined with extended (postdischarge) pharmacologic VTE prophylaxis after liver surgery. It is important to note that the vast majority of liver operations are performed for malignant indications. Likewise, the liver surgery performed for non-malignant indications also has a high-risk Caprini score. Also, although this study has limitations regarding single-center experience and a focus on oncologic liver surgery, this was a continuous series of patients without exclusions, and the thromboprophylaxis protocol was identical for both malignant and benign liver surgery indications. The results indicate that, across a broad spectrum of liver procedures performed on a total of 124 consecutive patients, no VTE or major bleeding events occurred during the study period, and the rate of non-major bleeding associated with pharmacologic prophylaxis was only 1.6%. These results were validated with both rigorous real-time collection of symptomatic events, and radiologic assessment in 90% of study patients within 90 days of surgery. Although these follow-up imaging studies were not dedicated to the detection of VTE, and may have missed infrainguinal lower-extremity DVT and/or small PEs, these studies were able to rule out major central thrombotic events. Such radiologic follow-up to identify asymptomatic events is rare in the postoperative VTE literature [25] [26] [27] [28] . It is of note that, among six patients who presented preoperatively on therapy for previous VTE, none experienced a symptomatic progression of thrombosis, and five of six had follow-up with high-quality intravenous contrast CT imaging that demonstrated improved (three, 50%) or resolved (two, 33%) thrombus.
Regarding immediate preoperative dosing, the American College of Chest Physician guidelines [29] describe a unique exclusion for preoperative dosing in procedures with extreme bleeding/transfusion risk, specifically commenting on hepatopancreaticobiliary surgery. Although our institution has reported a low rate of bleeding complications [30] , it is important to note that, nationally, 33% of liver resection patients are transfused [2] . For this reason, the published guideline for VTE prophylaxis in patients undergoing liver surgery indicates that preoperative dosing is optional [13] . Currently, in our practice, a preoperative dose is given when the indicated operation is a minor hepatectomy or a major hepatectomy with a low a priori risk of bleeding. Otherwise, patients are systematically started on chemical thromboprophylaxis when hemostasis is ensured, usually within a few hours of procedure completion (Fig. 1) .
The safety of any postoperative VTE prophylaxis regimen must be measured according to postoperative bleeding events, and particularly bleeding events requiring reintervention or red blood cell transfusion. With the use of a consistent strategy starting within 1 day of surgery and continuing for 2-4 weeks after surgery, the postoperative minor bleeding rates and postoperative transfusion rates were low (1.6% and 8%, respectively), and there were no patients who required reintervention for bleeding. Of the two postoperative bleeding events that were identified, neither occurred during the outpatient (extended) portion of the prophylaxis strategy. Together, these data indicate that this strategy is safe. Advanced diagnostic technologies, such as thromboelastography, may further widen the therapeutic index of anticoagulant thromboprophylaxis [16] .
On the basis of these data, our practice has now broadly adopted extended pharmacologic VTE prophylaxis as routine. Since the adoption of this, our internal data show a rate of inpatient and outpatient postoperative VTE events of <1%, and our recent risk-adjusted ACS-NSQIP hepatectomy data indicate that we are a low statistical outlier for VTE after hepatectomy. We attribute these data, (obtained in a cancer population at the highest risk for postoperative VTE events) to the perioperative, postoperative and now postdischarge VTE prophylaxis regimen described in this article (Fig. 1) .
Historically, in hepatic surgery practice, VTE prophylaxis was avoided completely or was started several days after surgery, when the INR had crested and started to decline. In contrast, this article reports a modern experience with initiation of thromboprophylaxis much earlier than this historical norm. The VTE prophylaxis regimen used in this study is similar to that reported by a collaboration between Duke University and University of Pittsburgh. Although they did not practice the routine use of postdischarge anticoagulant thromboprophylaxis, they observed a reduction in the rate of post-hepatectomy VTE with the utilization of postoperative anticoagulant thromboprophylaxis as compared with mechanical prophylaxis alone in liver surgery patients (2.2% versus 6.3%, respectively, P = 0.03) [31] . Similar to the findings reported in this study and others [16] , our results reaffirm the safety and suggest the efficacy of early postoperative initiation of pharmacologic thromboprophylaxis in liver patients. Although the sample size was small, the systematic administration of extended outpatient postdischarge thromboprophylaxis to a high-risk VTE population was associated with a zero event rate.
Clinical practice guidelines for VTE prophylaxis are variable. Although they are not specific to liver surgery, surgeons in the UK follow the National Institute for Health and Clinical Excellence (NICE) practice guidelines, which recommend the use of mechanical thromboprophylaxis with graduated compression stockings or intermittent compression devices in gastrointestinal surgery patients who have an increased risk for VTE [32] . Additionally, the NICE guidelines recommend administration of LMWH or low-dose unfractionated heparin in patients at low risk of major bleeding. Finally, both the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend that patients with major abdominal/pelvic cancer surgery receive pharmacologic VTE prophylaxis for 28 PODs [33, 34] .
Although there are randomized control trial results supporting the use of pharmacologic thromboprophylaxis in general surgery patients [35, 36] , there is a paucity of randomized control trials for pharmacologic thromboprophylaxis after liver resection. This preliminary observational study highlights the safety and potential effectiveness of extended anticoagulation after hepatectomy. To replicate these results, a multi-institution randomized study should be conducted to confirm that extended pharmacologic thromboprophylaxis beyond hospital discharge significantly reduces the rate of post-hepatectomy VTE. 
